110 related articles for article (PubMed ID: 27416702)
1. [Targeted therapy for mineral and bone disorder].
Komaba H; Fukagawa M
Nihon Jinzo Gakkai Shi; 2016; 58(4):581-6. PubMed ID: 27416702
[No Abstract] [Full Text] [Related]
2. Sclerostin monoclonal antibodies on bone metabolism and fracture healing.
Gamie Z; Korres N; Leonidou A; Gray AC; Tsiridis E
Expert Opin Investig Drugs; 2012 Oct; 21(10):1523-34. PubMed ID: 22849579
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies for the treatment of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2013 Feb; 13(2):183-96. PubMed ID: 23253281
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
Robinson MK; Caminis J; Brunkow ME
Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
[TBL] [Abstract][Full Text] [Related]
8. [Newly developed drugs to improve bone strength].
Hagino H
Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for bone diseases: translating bone biology into targeted therapy.
Tsourdi E; Rachner TD; Rauner M; Hamann C; Hofbauer LC
Eur J Endocrinol; 2011 Dec; 165(6):833-40. PubMed ID: 21852390
[TBL] [Abstract][Full Text] [Related]
10. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
Nakayamada S; Tanaka Y
Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
[TBL] [Abstract][Full Text] [Related]
11. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
Tanaka Y
Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
[TBL] [Abstract][Full Text] [Related]
12. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.
Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR
Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the inhibitor: a new route to bone anabolism.
Jilka RL
J Bone Miner Res; 2009 Apr; 24(4):575-7. PubMed ID: 19335216
[No Abstract] [Full Text] [Related]
14. [Serum sclerostin levels and metabolic bone diseases].
Yamauchi M; Sugimoto T
Clin Calcium; 2013 Jun; 23(6):877-83. PubMed ID: 23719501
[TBL] [Abstract][Full Text] [Related]
15. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
16. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
[TBL] [Abstract][Full Text] [Related]
17. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
18. Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders.
Dang L; Liu J; Li F; Wang L; Li D; Guo B; He X; Jiang F; Liang C; Liu B; Badshah SA; He B; Lu J; Lu C; Lu A; Zhang G
Int J Mol Sci; 2016 Mar; 17(3):428. PubMed ID: 27011176
[TBL] [Abstract][Full Text] [Related]
19. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Padhi D; Jang G; Stouch B; Fang L; Posvar E
J Bone Miner Res; 2011 Jan; 26(1):19-26. PubMed ID: 20593411
[TBL] [Abstract][Full Text] [Related]
20. [Anti-sclerostin antibodies].
Okazaki R
Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
